Cost Effectiveness Of Linezolid In Central America

Pfizer

Status: Withdrawn

Conditions: Ventilator Acquired Pneumonia

Treatments: Drug: Linezolid

Study type: Observational

Funder types: Industry

Identifiers

NCT01040585

A5951154

Details and patient eligibility

About

The therapy with Linezolid (LIN) represents better cost-effectiveness vs. Vancomycin (VAN) for the treatment of nosocomial Pneumonia associate to ventilator (VAP).

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Evidence of a legally acceptable representative signed and dated informed consent document indicating that him or her has been informed of all pertinent aspects of the study.
• Adult (18 years old or older) men and women with confirm diagnosis of VAP treated on ICU with LIN or VAN; on the selected institutions.

Exclusion criteria

• Adult men or women with nosocomial pneumonia not associated to a ventilator.

Trial design

0 participants in 1 patient group

Central America and the Caribbean

Description:

Panama, Costa Rica, Honduras, El Salvador and Nicaragua

Treatment:

Drug: Linezolid